Dupilumab therapy following JAK inhibitor withdrawal in moderate-severe atopic dermatitis.
Issue Date
2022-08-08Keywords
atopic dermatitisDermatology
Janus kinase inhibitors
Metadata
Show full item recordJournal
Dermatologic therapyDOI
10.1111/dth.15750PubMed ID
35906850Item Type
OtherLanguage
enEISSN
1529-8019ae974a485f413a2113503eed53cd6c53
10.1111/dth.15750
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis.
- Authors: Manzar D, Suntres E, Nair N, Patel Y, Abu-Hilal M
- Issue date: 2024 Jul
- Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab.
- Authors: Yang N, Chen L, Shao J, Jiang F, Liu J, Li Z
- Issue date: 2022 Nov
- Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
- Authors: Sedeh FB, Henning MAS, Jemec GBE, Ibler KS
- Issue date: 2022 Aug 24
- Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China.
- Authors: Song X, Liu B, Luan T, Liao S, Tan Y, Peng C, Zhao Z
- Issue date: 2023 Jun
- Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients.
- Authors: Achten R, Thijs J, van Luijk C, Knol E, Delemarre E, de Graaf M, Bakker D, de Boer J, van Wijk F, de Bruin-Weller M
- Issue date: 2023 Feb